Dr. DiGiovanna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 Howard Ave
Yale Physicians Building 2ND floor
New Haven, CT 06519Phone+1 203-688-4191Fax+1 203-737-2617
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1995 - 1997- Yale-New Haven Medical CenterResidency, Internal Medicine, 1991 - 1993
Yale School of MedicineClass of 1990
Certifications & Licensure
CT State Medical License 1993 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
Publications & Presentations
PubMed
- 2 citationsTrends in breast cancer specific death by clinical stage at diagnoses between 2000-2017.Michal Marczyk, Adriana Kahn, Andrea Silber, Mariya Rosenblit, Michael P Digiovanna
Journal of the National Cancer Institute. 2024-09-30 - 77 citationsTucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Bra...Nancy U Lin, Rashmi K Murthy, Vandana Abramson, Carey Anders, Thomas Bachelot
JAMA Oncology. 2023-02-01 - 76 citationsAdjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.Eleftherios P. Mamounas, Michael Untch, Max S. Mano, C.-S. Huang, Charles E. Geyer
Annals of Oncology. 2021-08-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
